BFRA - Biofrontera AG

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.38
0.00 (0.00%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close14.38
Open14.48
Bid14.50 x 800
Ask15.28 x 900
Day's Range14.38 - 14.38
52 Week Range11.04 - 18.32
Volume4
Avg. Volume3,170
Market Cap327.678M
Beta (3Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results

    Leverkusen, Germany, Aug. 14, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.

  • GlobeNewswire

    Biofrontera provides update on Cutanea integration

    Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, provides an update on the integration progress of Cutanea Life Sciences, Inc. (“Cutanea”). On March 25, 2019, Biofrontera Inc. through its wholly owned subsidiary Biofrontera Newderm LLC, acquired 100% of the stock of Cutanea, a specialty pharmaceutical company focused on dermatology products, from Maruho Co., Ltd. (“Maruho”). At the time of the acquisition, Maruho had agreed to cover any restructuring expenses as well as all other expenses during the three-month integration period, which ended on June 25, 2019, as well as to indemnify Biofrontera and Cutanea from any liabilities relating to or arising from the period prior to the closing.

  • GlobeNewswire

    Results of the voluntary partial tender offers

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the conclusion of the voluntary public partial tender offers of Maruho Deutschland GmbH as well as Deutsche Balaton Biotech AG and DELPHI Unternehmensberatung Aktiengesellschaft ("Offers"). On April 15, 2019, Maruho Deutschland GmbH published an offer to the shareholders of Biofrontera AG to acquire up to 4,322,530 of its registered non-par value shares in Biofrontera AG for a cash payment of EUR 6.60 per Biofrontera share.

  • GlobeNewswire

    Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the results of the Annual General Meeting held on 10 July 2019. The shareholders present represented 75.88% of the registered share capital. The shareholders approved the agenda items proposed by the Management Board and Supervisory Board (published in the Federal Gazette on June 3, 2019) with a large majority.

  • GlobeNewswire

    All Biofrontera Management Board members intend to fully accept the partial tender offer by Maruho Deutschland GmbH for their shares

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announces that the members of the Management Board, Prof. Dr. Hermann Lübbert, Thomas Schaffer and Christoph Dünwald, intend to tender all of their personally held Biofrontera AG shares to the partial tender offer by Maruho Deutschland GmbH. The Management Board would like to help Maruho Deutschland GmbH to successfully complete its offer and serve as an example for other shareholders.

  • GlobeNewswire

    Biofrontera to Present at Two Upcoming Investor Conferences

    Leverkusen, Germany, June 12, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced.

  • GlobeNewswire

    Biofrontera nominates new candidate for the Supervisory Board

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the agenda for the Annual General Meeting to be held on July 10, 2019 has been published. The Supervisory Board proposes that Prof. Dr. Franca Ruhwedel be elected to the Supervisory Board as successor to Hansjörg Plaggemars, who was dismissed as a member of the Supervisory Board by court order as of March 22, 2019. "As Professor of Finance and Accounting at the Rhine-Waal University of Applied Sciences, she has sound knowledge of accounting and risk management, which is very valuable for her work on the Supervisory Board.

  • ACCESSWIRE

    Biofrontera AG to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Biofrontera AG (NASDAQ: BFRA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 29, 2019 at 2:00 PM Eastern Time. ...

  • GlobeNewswire

    Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results

    Leverkusen, Germany, May 16, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.

  • GlobeNewswire

    Biofrontera Reports Full Year 2018 Financial Results

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the full year ended December 31, 2018 and provided an update on recent operational and clinical developments.

  • GlobeNewswire

    Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019

    Leverkusen, Germany, April 26, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today.

  • GlobeNewswire

    Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports positive results for the secondary endpoints of its Phase III clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz® in combination with the BF-RhodoLED® lamp for the treatment of actinic keratoses (AK) on the extremities or trunk/neck. In line with the result for the primary endpoint of the study (see ad hoc report dated March 20, 2019), which showed a mean lesion clearance rate per patient’s side of 86% for Ameluz® compared to 33% for placebo, significant superiority of Ameluz® was demonstrated for all secondary parameters investigated. In patients treated on the extremities, mean lesion clearance rates per patient’s side were also 84% with Ameluz® compared to 27% with placebo.

  • GlobeNewswire

    Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

    Leverkusen, Germany, April 16, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be.

  • GlobeNewswire

    Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports preliminary unaudited revenue for the first three months of fiscal year 2019. The preliminary unaudited revenue of the Company for the period January to March 2019 was around EUR 6.8 million. This represents a revenue growth of approximately 46% compared to the previous year period, with pure product sales increasing by around 48%.

  • GlobeNewswire

    Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH

    Leverkusen, Germany, April 02, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about.

  • GlobeNewswire

    Changes in the composition of the Supervisory Board

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Local District Court (Amtsgericht) dismissed Mr. Hansjörg Plaggemars as a member of the Supervisory Board of Biofrontera AG in accordance with § 103 (3) AktG for cause. In January 2019, the Supervisory Board of Biofrontera AG filed an application with the Cologne Local Court to dismiss Mr. Plaggemars.

  • GlobeNewswire

    Biofrontera provides corporate update; conference call details for March 26, 2019

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a conference call to be held tomorrow to provide a detailed corporate update on its acquisition of Cutanea Life Sciences, Inc. (“Cutanea”). As announced earlier today, Biofrontera acquired 100% of the stock of Cutanea, a specialty pharmaceutical company focused on dermatology products from Maruho Co., Ltd. (“Maruho”). This transaction is expected to strengthen Biofrontera’s U.S. market presence and allow it to compete more effectively in the U.S. dermatology market by adding Cutanea’s products and expertise to its existing core business.

  • GlobeNewswire

    Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA

    Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA (“Cutanea”) through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan (“Maruho”) as the seller. Cutanea is a US-based pharmaceutical company specializing in dermatology.

  • GlobeNewswire

    Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

    Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical.

  • GlobeNewswire

    Biofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz®

    Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to continue the expired research cooperation with Maruho Co., Ltd., Osaka, Japan (“Maruho”) regarding branded generics. As part of the newly agreed project phase Biofrontera will prepare the formulation of one of the four active ingredients in Biofrontera’s nanoemulsion jointly tested during a previous project phase (Phase 1) for clinical trials.

  • GlobeNewswire

    Biofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year

    Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that its wholly owned US-subsidiary Biofrontera Inc. earned a Silver Stevie Award for outstanding Customer Service Department of the Year - Healthcare, Pharmaceuticals, and Related Industries. The Stevie Awards for Sales & Customer Service are the world's top honors for customer service, contact center, business development, and sales professionals.

  • GlobeNewswire

    Biofrontera implements new Falsified Medicines Directive

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has implemented all necessary safety measures defined in the new Commission Delegated Regulation (EU) 2016/161 to fight medicine falsifications. Since the Regulation came into force on February 9, 2019, only prescription drugs for human use with the safety features of the Commission Delegated Regulation (EU) 2016/161 may be released for marketing. "The implementation of the Falsified Medicines Directive throughout the pharmaceutical supply chain will contribute to one thing in particular: the safety of prescription drugs.

  • GlobeNewswire

    Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018

    Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, Jan. 22, 2019 -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international.

  • GlobeNewswire

    Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA), and earlier the European Medicines Agency (EMA), have approved the upscaling of the batch size for the production of Ameluz® to 35 kg from previously 7 kg. “The approval for a 5-fold increase in batch size ensures a secure supply of Ameluz® to meet the growing demand for Ameluz® in all regions.

  • GlobeNewswire

    Ruling by the U.S. District Court of Massachussetts

    Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today comments on a court order issued by the U.S. District Court of Massachussetts. Biofrontera is currently involved in litigation with DUSA Pharmaceuticals. DUSA sued Biofrontera in the U.S. District Court of Massachusetts.